The role of PET/CT imaging in penile cancer

Abstract

Positron emission tomography (PET) imaging with ¹⁸F-fluorodeoxyglucose (FDG) combined with computed tomography (CT) provides functional imaging combined with anatomic information, improving diagnostic accuracy and confidence. Although virtually all primary penile tumors are FDG-avid, PET/CT is not recommended for primary tumor staging as it has limited spatial resolution and is hampered by urinary FDG excretion. The accuracy of PET/CT for lymph node staging seems to improve with the pretest likelihood of metastatic nodes. In groins with normal physical examination, sensitivity is only 57%. In groins with palpably enlarged lymph nodes, sensitivity of PET/CT reaches 96%. For pelvic lymph nodes and distant metastases, PET/CT is more accurate if inguinal metastases are present. However, these results are based on a very limited number of studies. Overall, the role of PET/CT imaging in penile cancer remains ambiguous, especially in inguinal lymph nodes. During staging and follow-up, it may be particularly useful in detecting pelvic lymph node metastases and occult distant metastases prior to systemic chemotherapy and/or extensive surgery, improving selection of patients that are most likely to benefit from such therapies.

Introduction

Cancer of the penis is a rare disease with an incidence of 0.6–2.1 in Western countries (1-3). The majority of these cancers are squamous cell carcinoma, but other histological types and subtypes such as basaloid and warty squamous cell, and melanoma can occur. The worldwide incidence has significant geographic variations, which is mainly explained by circumcision, sexual practices and socioeconomic circumstances (2).

Imaging and other staging techniques have improved the risk stratification of penile cancer. Ultrasound-guided fine needle aspiration biopsy, (dynamic) sentinel node biopsy, and various forms of lymph node dissections are invasive techniques that have improved lymph node staging. In addition, axial imaging such as CT, MRI and PET/CT have also evolved in the past decades.

Positron emission tomography (PET) imaging with ¹⁸F-fluorodeoxyglucose (FDG) is based on cellular uptake of glucose and FDG, which is elevated in malignant cells and other tissues with an elevated glycolytic rate (4). FDG-PET combined with computed tomography (CT) provides functional imaging combined with anatomic information, improving diagnostic accuracy and confidence. PET/CT scanners acquire PET and CT images in a single scanner, and are nowadays widely used.

In various malignant diseases, PET/CT is used for staging and monitoring. Combining functional with anatomical imaging, PET/CT outperforms both PET alone and CT alone in lymph node staging of many types of tumors (5-7). Here we review the role of PET/CT in the diagnosis and management of penile cancer.

In penile cancers, both the primary tumors and lymph node metastases generally show high uptake of FDG. Hence, suitability for staging penile cancer is likely (8). However, sensitivity of PET/CT is limited by its spatial resolution, reducing sensitivity for small metastases. In addition, false-positives may occur due to inflammation, such as in reactive lymph nodes.

Primary tumor staging

In their first study on PET in penile cancer, Scher et al. found that only 6 out of 8 primary tumors were detected by FDG-PET/CT (8), but this can be explained by the small size of the two undetected tumors, which was below the spatial resolution of PET (one residual lesion after incomplete resection of a T1 tumor, and one very small (<0.5 cm) T1 tumor. The authors even describe that in retrospect both lesions did show some FDG-uptake.

In our experience, almost all primary penile tumors are FDG-avid. An example is shown in Figure 1. However, PET/CT is not very useful for primary tumor staging, because its limited spatial resolution makes it unsuitable for evaluating ingrowth in surrounding structures or even the exact size of the tumor. Additionally, FDG is excreted via the urine, which can interfere with imaging of the primary tumor. Physical examination and, in selected cases MRI, have excellent accuracy for staging primary penile tumors (9).

Figure 1.

FDG-PET/CT of a penile cancer patient. The primary tumor exhibits high FDG uptake (SUVmax 11.7).

Lymph node staging

The diagnostic value of FDG-PET/CT for lymph node staging varies in different types of cancer. Often, reported sensitivities are higher than for conventional modalities such as CT and MRI, but are not always satisfactory (4). In pancreatic cancer for example, PET/CT shows a sensitivity in N-staging of only 30% (10). Somewhat better results appear in clinically lymph node negative non-small cell lung cancer (stage I) and head and neck cancer (cN0) patients, with sensitivities for regional lymph nodes of 57% and 67% respectively (11,12). Specificities may be higher, but identification of patients where invasive staging or therapy can be omitted requires high sensitivity.

Inguinal lymph nodes

Non-palpable lymph nodes

Detection of inguinal involvement using FDG-PET/CT in penile cancer patients that were initially staged as node negative (cN0) was evaluated in several studies.

In 2005, Scher et al. examined thirteen mostly cN0 patients. Of 16 positive lymph nodes, FDG PET/CT correctly identified 15 as positive, with only one false negative lesion, resulting in a sensitivity per lesion of 94%. The sensitivity for superficial inguinal lymph nodes was 89% per lesion and 80% per patient (8).

Later, Leijte et al. published PET/CT results of solely cN0 groins. Five out of 42 groins had lymph node metastases, but PET/CT only identified one, resulting in a sensitivity of only 20%. The true positive lymph node metastasis was larger than the other four (30 vs. 10, 10, 1 and 1 mm). This study emphasizes the limited sensitivity of PET/CT in detecting small metastases (13).

In 2012, Souillac et al. showed better sensitivity for PET/CT in cN0 patients, albeit in a small set of patients. PET/CT correctly identified 3 out of 4 metastases (75% sensitivity) (14).

In all these three studies, specificity of PET/CT was higher than sensitivity: Scher et al. 100%, Leijte et al. 92% and Souillac et al. 88%. Negative predictive values (NPV) were 89%, 90% and 83% respectively.

In a meta-analysis of seven studies by Sadeghi et al., the pooled sensitivity per groin for FDG-PET/CT in cN0 patients was only 57% (15). Positive predictive values were also disappointing (between 25 and 37 percent). Therefore, surgical staging is necessary to identify small inguinal lymph node metastases and FDG-PET/CT is not recommended for staging of cN0 patients (8,13-15).

Palpable lymph nodes

For patients that present with palpable lymph nodes in the groin, PET/CT has a different clinical value (Figure 2). The aforementioned meta-analysis by Sadeghi et al. found that detection of inguinal metastases with FDG-PET/CT in clinically suspicious groins had a pooled sensitivity and specificity of 96 and 100% per groin respectively (15). Thus, PET/CT is more accurate in patients with palpable lymph nodes. Assessing the number of lymph nodes involved with PET/CT may be useful when neoadjuvant chemotherapy will be considered in case of multiple or bulky inguinal metastases (16).

Figure 2.

FDG-PET/CT of the same penile cancer patient, who was clinically staged as positive for inguinal lymph node metastases (cN+). The PET shows extensive pelvic lymph node metastases. Bilateral inguinal metastases were also FDG-positive.

Pelvic lymph nodes

On pelvic lymph nodes, literature is scarce. In a study on 18 patients with proven inguinal metastases, the diagnostic accuracy of FDG-PET/CT was evaluated for staging pelvic lymph nodes (17). The clinical benchmark this was compared to was either histopathology, clinical follow-up, or radiologic imaging. Twenty-eight of 36 pelvic basins were eligible for analysis, and results were good. Analysis showed a sensitivity of 91%, specificity of 100%, and similar negative and positive predictive values (94 and 100 percent respectively). FDG-PET/CT gave a correct prediction in 96%. This is the only study that provides numbers on pelvic lymph node evaluation of PET/CT.

In stage 3 and 4 patients, Zhang et al. showed good results for lymph nodes (all locations) with a sensitivity of 93% and a specificity of 85% (18). Also in other malignancies and lymph node areas, results suggest that FDG-PET/CT has higher accuracy than CT only in staging pelvic lymph nodes (5,6,19,20). However, results are not always optimistic. A prospective multicenter trial in advanced cervical cancer found no significant improvement of sensitivity nor specificity for detection of pelvic lymph node metastases with adding FDG-PET/CT to diagnostic contrast enhanced CT (21). In addition, Lin et al. found lower diagnostic accuracy for PET/CT than CT or MRI in a per scan receiver operating characteristic (ROC) curve analysis for metastatic pelvic lymph nodes or distant metastases in vulvar carcinoma (22).

Distant metastases

Literature on distant penile cancer metastases detected with FDG-PET/CT consists largely of case reports (23-26). In the aforementioned study by Graafland et al. among 18 patients with pathologically confirmed inguinal lymph node metastases, five patients were diagnosed with distant metastases by PET/CT (17). Four of these five metastases were confirmed with either CT alone or histopathology (17). Although this was a small number of patients, these results suggest that PET/CT is useful for accurate M-staging.

The largest series by Zhang et al. [2016] compared FDG-PET/CT to conventional CT in 42 patients with suspicious lesions on CT or MRI, leading to an implicit selection bias (18). With histopathology or follow-up imaging as a reference, sensitivity and specificity of FDG-PET/CT were 85% and 86% respectively for all metastatic sites, including lymph nodes, lung, bone, etc. In a patient-based analysis this was 82% and 93% respectively. Drawbacks of this study are a short follow-up of patients as well as the aforementioned selection bias.

The whole body imaging aspect of PET/CT scanning can be of crucial impact on clinical decision making. If distant metastases are found in patients scheduled for locoregional therapy (Figure 3), this changes their indicated treatment to systemic or palliative regimens (18).

Figure 3.

FDG-PET/CT of the same penile cancer patient, showing a solitary skeletal metastasis in the 8th thoracic vertebra, which was not visible on CT. In addition, extensive mediastinal and hilar lymphadenopathy was visible with small pulmonary and pleural lesions, which were thought to be possible sarcoidosis or metastases. Follow-up CT after 3 months showed gross progression, with multiple metastases in bone, liver, spleen and pelvic lymph nodes. In contrast, the lesions in the lungs and mediastinum were stable, increasing the likelihood of those being caused by a separate process such as sarcoidosis.

Other settings

Surveillance

In general, surveillance after treatment of penile cancer depends on physical examination by the physician and the patient himself. In our experience, PET/CT can be of value for identification of the location and extent of suspected recurrence. Routine surveillance with PET/CT is not recommended.

Combined modalities

A recent study with 129 patients used FDG-PET/CT scanning complementary to sentinel node biopsy (27). In this cohort, FDG-PET/CT found one additional metastatic lymph node that was not detected with the radiotracer of the sentinel node biopsy procedure. The combined procedure had a sensitivity of 94%, reducing the false negative rate to an acceptable level.

Conclusions and future perspectives

In conclusion, the exact role of FDG-PET/CT imaging in penile cancer remains ambiguous. So far, PET/CT has shown to have significant limitations, especially in inguinal lymph node staging. Results seem to improve with the pre-test likelihood of metastatic involvement.

PET/CT may be particularly useful in assessing pelvic metastases and occult distant metastatic burden prior to systemic chemotherapy and/or prior to an extensive surgical resection. This would improve the selection of those who are most likely to benefit from an aggressive multimodal approach. However, evaluation of this indication for FDG-PET/CT in larger cohorts is warranted (28).